EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Randomization in phase II trials: No exemption based on sample size

Theodor Framke iD, Gernot Beutel, Arnold Ganser, Armin Koch, Anika Großhennig iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Theodor Framke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biostatistics, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genzyme, Federal Ministry of Education and Research, Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conducting randomized clinical trials (RCTs) is challenging. For this reason, in earlier phases of drug development and rare diseases with limited sample sizes, there is a tendency to omit control groups and to replace them with historical information for perceived feasibility arguments. This has significant implications for interpretation of trial results. We present headline results from a trial in stem cell transplantation, where fludarabine and clofarabine were investigated for induction chemotherapy in high‐risk acute myeloid leukaemia or advanced myelodysplastic syndrome. The trial was initially designed as single‐arm trial (SAT) and is discussed here from the planning and assessment perspective. Changes in the treatment setting or patient selection may lead to ‘promising results’ in SATs, which are difficult to identify and may raise unwarranted hopes which cannot be confirmed in a subsequent randomized trial. RCTs should be used to achieve a straightforward interpretation of the results, even if the sample size is small. Interpreting SATs is only straightforward in very rare instances where the underlying treatment effect is large and the outcome in each individual patient surpasses all previous clinical experience.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteRandomized Controlled Trials as TopicClinical Trials, Phase II as TopicAntineoplastic Combined Chemotherapy ProtocolsHumansSample SizeResearch DesignVidarabineClofarabinePatient SelectionInduction Chemotherapy

Stichwörter der Autor:innen

AML/MDSclofarabinedrug development programmeevidentiary standardsfludarabinephase 2randomization

Substanzen

fludarabineVidarabineClofarabine

Autor:innen und Institutionen

  • Institute for Biostatistics, Hannover Medical School, Hannover, Germany.
  • Department for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

ORCID-Profile: Theodor Framke, Anika Großhennig

Förderung

  • Genzyme
  • Federal Ministry of Education and Research
  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Framke, T., Beutel, G., Ganser, A., Koch, A., & Großhennig, A. (2025). Randomization in phase II trials: No exemption based on sample size. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70167

Vancouver

Framke T, Beutel G, Ganser A, Koch A, Großhennig A. Randomization in phase II trials: No exemption based on sample size. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70167

BibTeX
@article{Framke2025,
  author = {Framke, Theodor and Beutel, Gernot and Ganser, Arnold and Koch, Armin and Großhennig, Anika},
  title = {Randomization in phase II trials: No exemption based on sample size},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70167}
}
Kostenlos starten →